NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ABUS Stock Alerts $3.29 +0.01 (+0.30%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$3.23▼$3.3250-Day Range$2.49▼$3.4152-Week Range$1.69▼$3.44Volume548,649 shsAverage Volume791,906 shsMarket Capitalization$620.89 millionP/E RatioN/ADividend YieldN/APrice Target$4.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arbutus Biopharma alerts: Email Address Arbutus Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside31.7% Upside$4.33 Price TargetShort InterestBearish3.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.39) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.27 out of 5 starsMedical Sector758th out of 923 stocksPharmaceutical Preparations Industry357th out of 429 stocks 3.5 Analyst's Opinion Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Arbutus Biopharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.08% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Arbutus Biopharma has recently increased by 12.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABUS. Previous Next 2.6 News and Social Media Coverage News SentimentArbutus Biopharma has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search Interest11 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Arbutus Biopharma is held by insiders.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arbutus Biopharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.39) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -7.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -7.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 5.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arbutus Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsWARNING about the death of the U.S. dollar…Where do you turn during times of economic uncertainty? Many elites trust storing their wealth in gold (which has historically boomed when the dollar’s value has plummeted!)Get Colonial Metals' new Precious Metals Investment Guide. About Arbutus Biopharma Stock (NASDAQ:ABUS)Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Read More ABUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABUS Stock News HeadlinesMay 25 at 7:50 AM | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Stock Price Down 4.7%May 24 at 6:44 AM | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Hits New 12-Month High at $3.29May 22, 2024 | globenewswire.comArbutus to Present Imdusiran Data at EASL Congress 2024May 17, 2024 | morningstar.comArbutus Biopharma Corp ABUSMay 17, 2024 | bizjournals.comMike Sofia, who discovered cure for hepatitis C, set to retire from Arbutus BiopharmaMay 17, 2024 | finance.yahoo.comArbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B ProgramMay 17, 2024 | finance.yahoo.comUpdate: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B ProgramMay 17, 2024 | businesswire.comWhitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize ValueMay 10, 2024 | msn.comArbutus Biopharma to Engage Investors at Upcoming New York ConferencesMay 7, 2024 | globenewswire.comArbutus to Participate in Two Upcoming Investor ConferencesMay 3, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)May 3, 2024 | finance.yahoo.comArbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 3, 2024 | finance.yahoo.comArbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2024 | finance.yahoo.comArbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call TranscriptMay 3, 2024 | msn.comArbutus Biopharma Makes Headway in Hepatitis B Treatment and Defends Intellectual Property Amidst Q1 2024 Financial ReleaseMay 2, 2024 | finance.yahoo.comArbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial ReviewMay 2, 2024 | investorplace.comABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024May 2, 2024 | washingtonpost.comArbutus: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comArbutus Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 2, 2024 | globenewswire.comArbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024May 1, 2024 | markets.businessinsider.comArbutus Biopharma earnings: here's what to expectMay 1, 2024 | msn.comArbutus Biopharma Q1 2024 Earnings PreviewApril 30, 2024 | money.usnews.comArbutus Biopharma CorpApril 21, 2024 | msn.comArbutus Biopharma Sets Date for Q1 2024 Financial ResultsApril 18, 2024 | globenewswire.comArbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateSee More Headlines Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABUS CUSIPN/A CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees73Year Founded1992Price Target and Rating Average Stock Price Target$4.33 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+31.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,850,000.00 Net Margins-572.81% Pretax Margin-572.81% Return on Equity-62.68% Return on Assets-47.22% Debt Debt-to-Equity RatioN/A Current Ratio6.69 Quick Ratio6.69 Sales & Book Value Annual Sales$18.14 million Price / Sales34.23 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book5.39Miscellaneous Outstanding Shares188,720,000Free Float181,168,000Market Cap$620.89 million OptionableOptionable Beta2.05 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Michael J. McElhaugh (Age 49)Co-Founder, Interim President, CEO & Director Comp: $606.62kDr. Michael J. Sofia Ph.D. (Age 66)Chief Scientific Officer Comp: $628.43kMr. David C. Hastings CPA (Age 63)CFO & Chief Accounting Officer Comp: $647.1kMs. Lisa M. CaperelliVice President of Investor RelationsMr. J. Christopher Naftzger BA (Age 57)Esq., J.D., General Counsel, Chief Compliance Officer & Secretary Ms. Shannon Briscoe SPHRVice President of Human ResourcesDr. Karen Sims M.D. (Age 53)Ph.D., Chief Medical Officer Mr. R. Hector Mackay-Dunn B.A. (Age 73)J.D., L.L.B., Q.C., Corporate Secretary More ExecutivesKey CompetitorsPharming GroupNASDAQ:PHARORIC PharmaceuticalsNASDAQ:ORICSavaraNASDAQ:SVRAPhathom PharmaceuticalsNASDAQ:PHATHarrowNASDAQ:HROWView All CompetitorsInstitutional OwnershipWhitefort Capital Management LPSold 334,910 shares on 5/17/2024Ownership: 6.815%Tidal Investments LLCBought 43,155 shares on 5/17/2024Ownership: 0.023%Walleye Trading LLCBought 14,000 shares on 5/17/2024Ownership: 0.007%Kennedy Capital Management LLCBought 49,265 shares on 5/16/2024Ownership: 0.231%California State Teachers Retirement SystemSold 8,117 shares on 5/16/2024Ownership: 0.007%View All Institutional Transactions ABUS Stock Analysis - Frequently Asked Questions Should I buy or sell Arbutus Biopharma stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABUS shares. View ABUS analyst ratings or view top-rated stocks. What is Arbutus Biopharma's stock price target for 2024? 3 brokerages have issued 12 month price objectives for Arbutus Biopharma's shares. Their ABUS share price targets range from $4.00 to $5.00. On average, they expect the company's stock price to reach $4.33 in the next twelve months. This suggests a possible upside of 31.7% from the stock's current price. View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts. How have ABUS shares performed in 2024? Arbutus Biopharma's stock was trading at $2.50 at the beginning of 2024. Since then, ABUS stock has increased by 31.6% and is now trading at $3.29. View the best growth stocks for 2024 here. When is Arbutus Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our ABUS earnings forecast. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Co. (NASDAQ:ABUS) posted its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The biopharmaceutical company earned $1.53 million during the quarter, compared to analysts' expectations of $2.16 million. Arbutus Biopharma had a negative net margin of 572.81% and a negative trailing twelve-month return on equity of 62.68%. What ETFs hold Arbutus Biopharma's stock? ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Morningstar US Small Growth (MSGR).Amplify Treatments, Testing and Advancements ETF (GERM). What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO? 6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX). Who are Arbutus Biopharma's major shareholders? Arbutus Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Whitefort Capital Management LP (6.82%), Kennedy Capital Management LLC (0.23%), BNP Paribas Financial Markets (0.19%), Susquehanna Fundamental Investments LLC (0.05%), Tidal Investments LLC (0.02%) and Verus Capital Partners LLC (0.02%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABUS) was last updated on 5/26/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaWARNING about the death of the U.S. dollar…Colonial Metals$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsBiden replacement revealed?Paradigm PressNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTradeThe only AI company to buyPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.